Fixing the paradigm for biopharmaceutical R&D: Where to start? Online publication date: Tue, 18-Nov-2008
by Christopher-Paul Milne
International Journal of Biotechnology (IJBT), Vol. 10, No. 5, 2008
Abstract: The basic thesis of this paper is that the R&D sector of the new medicines' business is experiencing evolutionary stress. Due to the failure of the regulatory framework and applied sciences to keep pace with advances in discovery, there is a bottleneck in the development phase of R&D. While improved process may help, there are still problems related to the products themselves, such as the need to move from a population-based model of product development, in which one size fits all, to a more targeted approach based on specialty drugs for patient subpopulations. The old paradigm dominated by big pharma and blockbusters must evolve, in order for a new bio-pharmaceutical paradigm to emerge. Despite the challenge that the fates of the pharmaceutical and biotech sectors are currently intertwined, it may be the dark before the dawn that betokens real change.
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Biotechnology (IJBT):
Login with your Inderscience username and password:
Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.
If you still need assistance, please email subs@inderscience.com